HGS has a wide range of targets and technologies available for licensing. While we are internally developing a number of human protein and antibody product candidates, we are actively seeking outlicensing partners for the development of additional product candidates. Our existing partners have advanced a number of products derived from our technology to clinical development; we welcome the opportunity to establish new collaborations.

Available Technology

Potential Indications:

• All Indications (296)
• Bone (17)
• Cancer (162)
• Cardiovascular (33)
• HIV (2)
• Immune (118)
• Infection (16)
• Inflammation (51)
• Neurological (55)
• Other (71)

Additional technologies not listed, including antibody and albumin fusion technologies, may also be available for licensing. Please direct inquiries to This e-mail address is being protected from spam bots, you need JavaScript enabled to view it . Inquiries may also be directed to 301/ 315-1790 (phone) or 301/354-3342 (fax).